Wang Tianyuan, CEO of ClickMab Biotech: Click.mAb — A Precise, Efficient, and User-Friendly AI Agent Platform for End-to-End Antibody Drug Discovery
Clickmab
Early-stage Antibody Drug Developer
Chinese Biopharmaceutical Association - USA, China Chapter (CBA-China)Always committed to building a bridge connecting China and the US, integrating Eastern and Western academia and industry. Based on the global wave of biopharmaceutical innovation, focusing on industry pain points and future trends, we willMay 8-10InWuxi International Convention CenterHold2026 CBA-China Annual Conference in China。The conference was themed "Breaking the Deadlock, Symbiosis for a Healthier Future —— Addressing Global Changes, Building a New Ecosystem for Drug Innovation and Accessibility" as the theme, bringing together 260+ authoritative guests from home and abroad, 4000+ industry elites, and meticulously crafting 13 parallel forums, coveringEarly Development、Clinical Translation、Global Registration、CGT、ADC、AI Drug Discovery、Investment and Financing BDThe core tracks of the entire industrial chain. From frontier technology analysis to industry policy interpretation, from project对接 to capital cooperation, the complete agenda fully presents the global pharmaceutical innovation ecosystem, offering industry peers a high-standard, all-dimensional, and deeply informative annual intellectual feast.
Clickmab CEO Tianyuan WangWill attend this conference and on the afternoon of May 9th "AI-Driven Structural Biology Revolution Accelerates the Discovery of Innovative Drug Targets and Precise R&D"Forum Keynote Speech Report:Click.mAb: A Precise, Efficient, and User-Friendly AI-Powered Platform for the Entire Antibody Drug Development Process。
Dr. Tianyuan Wang, currently the CEO of Clickmab and former head of biopharmaceuticals at XtalPi, graduated with a bachelor's degree from the University of Science and Technology of China and conducted research on protein engineering and protein design during his Ph.D. at the Institute of Biophysics, Chinese Academy of Sciences. At Clickmab, Dr. Tianyuan Wang led his team to independently develop an antibody de novo design algorithm based on generative AI, as well as a multi-agent antibody design platform powered by large language models, named Click.mAb. This platform completed the world’s first proof-of-concept for dry-wet integration in the de novo design of antibodies targeting specific epitopes, achieving accuracy comparable to that of David Baker’s team, the 2024 Nobel Prize winner. Dr. Tianyuan Wang has years of experience in AI + macromolecule algorithm development, implementing AI in biopharmaceutical R&D, managing cross-disciplinary teams, and incubating projects driven by cutting-edge technologies alongside industry-academia-research translation.
Conference Name:2026CBA-China Annual Conference in China
Hosted by:Chinese Biopharmaceutical Association - USA, China Chapter (CBA-China)
Organizer:BioValley
Conference Time:May 8-10, 2026 (Friday-Sunday)
Venue:Wuxi International Convention Center
Scale of the Conference:4,000 People
Participants:Biopharmaceutical companies, project management and senior company executives, registration and overseas personnel, research institutes and hospitals, investment and consulting agencies, factory construction and clean equipment.
Scan to Register
*From now until April 30, 2026, registration is free;Starting from May 1st, the conference registration fee will be 100 yuan per person;
*Forward this post to your Moments, collect 18 likes, and redeem a meal voucher or a精美礼品on-site. Limited quantity, first come, first served.
Conference Agenda Preview
CBA-China 2026
Agenda Unveiled with a Bang
CBA-China 2026
The specific agenda is subject to change; please refer to the final announcement...
Limited-time Free Registration Channel
(From now until April 30)
Scan the code to enter the conference group chat
(Note CBA2026)
| Business Cooperation
Stephen Sun
T: 15966587556
E: sunhx@biovalleyclub.com
| Academic Report
Seven Lu
T: 13641798663
E: tianyi.lu@biovalleyclub.com
| Media Cooperation / Conference Attendance Consultation
Abby Jiang
T: 18217659261
E: xiaolang.jiang@biovalleyclub.com
About CBA
Chinese-American Biopharmaceutical Association(Chinese Biopharmaceutical Association-USA, abbreviated as CBA) was founded in 1995 and is the largest Chinese-American professional association in the biopharmaceutical field in the United States.
The primary mission of CBA is to serve as a bridge for cooperation between the United States and China in the biopharmaceutical field, promote comprehensive exchange among professionals in the pharmaceutical industries of both countries, and provide a favorable environment for the development and collaboration of biopharmaceutical companies and research institutions.
CBA members come from a variety of sources, including emerging technology companies in the U.S. and China, multinational pharmaceutical corporations, universities, research institutions, government pharmaceutical regulatory agencies, various support funds for research or industrial development, and professional organizations specializing in law and intellectual property. Over 80% of CBA members hold a Ph.D.
CBA has a good reputation internationally, with members遍布世界各地, including China, the United States, Europe, Canada, Australia, Singapore, and Japan. Currently, it has accumulated more than 10,000 individual members and over 1,000 corporate members.
CBA has a close relationship with the U.S. Food and Drug Administration (FDA). Many of its presidents have worked at the FDA and are familiar with international biopharmaceutical registration strategies and other regulations. It also has particularly strong ties with the University of Maryland, Johns Hopkins University, and their medical schools. Additionally, Jiangsu Province and Maryland State share a sister-state relationship.
Thanks to the support of the following cooperative media
Click "Read the original text", sign up now~